213 related articles for article (PubMed ID: 19778522)
1. Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Togano T; Sasaki M; Watanabe M; Nakashima M; Tsuruo T; Umezawa K; Higashihara M; Watanabe T; Horie R
Biochem Biophys Res Commun; 2009 Dec; 390(1):60-4. PubMed ID: 19778522
[TBL] [Abstract][Full Text] [Related]
2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
3. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
4. Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Ruan HY; Masuda M; Ito A; Umezawa K; Nakashima T; Yasumatsu R; Kuratomi Y; Yamamoto T; Weinstein IB; Komune S
Head Neck; 2006 Feb; 28(2):158-65. PubMed ID: 16355386
[TBL] [Abstract][Full Text] [Related]
5. Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Kimura N; Miyakawa Y; Kohmura K; Umezawa K; Ikeda Y; Kizaki M
Leuk Res; 2007 Nov; 31(11):1529-35. PubMed ID: 17466373
[TBL] [Abstract][Full Text] [Related]
6. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
[TBL] [Abstract][Full Text] [Related]
7. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB inhibition enhances caspase-3 degradation of Akt1 and apoptosis in response to camptothecin.
He L; Kim BY; Kim KA; Kwon O; Kim SO; Bae EY; Lee MS; Kim MS; Jung M; Moon A; Bae K; Ahn JS
Cell Signal; 2007 Aug; 19(8):1713-21. PubMed ID: 17462862
[TBL] [Abstract][Full Text] [Related]
9. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Horiguchi Y; Kuroda K; Nakashima J; Murai M; Umezawa K
Expert Rev Anticancer Ther; 2003 Dec; 3(6):793-8. PubMed ID: 14686701
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Ohsugi T; Horie R; Kumasaka T; Ishida A; Ishida T; Yamaguchi K; Watanabe T; Umezawa K; Urano T
Carcinogenesis; 2005 Aug; 26(8):1382-8. PubMed ID: 15831528
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
14. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
Wong JH; Lui VW; Umezawa K; Ho Y; Wong EY; Ng MH; Cheng SH; Tsang CM; Tsao SW; Chan AT
Cancer Lett; 2010 Jan; 287(1):23-32. PubMed ID: 19560263
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
Mino K; Ozaki M; Nakanishi K; Haga S; Sato M; Kina M; Takahashi M; Takahashi N; Kataoka A; Yanagihara K; Ochiya T; Kamiyama T; Umezawa K; Todo S
Cancer Sci; 2011 May; 102(5):1052-8. PubMed ID: 21288284
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
[TBL] [Abstract][Full Text] [Related]
17. Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
Ohsugi T; Kumasaka T; Okada S; Ishida T; Yamaguchi K; Horie R; Watanabe T; Umezawa K
Cancer Lett; 2007 Nov; 257(2):206-15. PubMed ID: 17764832
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Kuroda K; Horiguchi Y; Nakashima J; Kikuchi E; Kanao K; Miyajima A; Ohigashi T; Umezawa K; Murai M
Clin Cancer Res; 2005 Aug; 11(15):5590-4. PubMed ID: 16061877
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
20. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
